Results 171 to 180 of about 1,991 (194)
Some of the next articles are maybe not open access.
Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients
Trends in Pharmacological Sciences, 2023Nicole Zatorski +2 more
openaire +2 more sources
Mavacamten en miocardiopatía hipertrófica obstructiva sintomática
Panorama Actual del MedicamentoMavacamten es un inhibidor selectivo, alostérico y reversible de la miosina cardiaca. Mavacamten modula el número de cabezas de miosina que pueden entrar en estados generadores de fuerza, reduciendo así la probabilidad de formación de puentes cruzados sistólicos productores de fuerza y diastólicos residuales.
openaire +1 more source
Mavacamten for Obstructive Hypertrophic Cardiomyopathy in China
JAMA Cardiology, 2023openaire +2 more sources
MAVACAMTEN IN HYPERTROPHIC CARDIOMYOPATHY: EFFECTIVE, BUT AFFORDABLE?
Journal of the American College of Cardiology, 2023Shivani Hanchate +4 more
openaire +1 more source
Proceedings of the National Academy of Sciences of the United States of America, 2018
Darshan V Trivedi +2 more
exaly
Darshan V Trivedi +2 more
exaly
ICER assessing mavacamten for hypertrophic cardiomyopathy
PharmacoEconomics & Outcomes News, 2021openaire +1 more source
Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin
Proceedings of the National Academy of Sciences of the United States of America, 2018Osha Roopnarine, David D Thomas
exaly
Reflections on community experience with Mavacamten
Progress in Cardiovascular DiseasesClement, Eiswirth, Yvonne E, Gilliland
openaire +2 more sources
A Collaborative Approach to Mavacamten Care: A Pharmacist-Nurse Led Mavacamten Monitoring Program
Heart, Lung and CirculationV. Warner +11 more
openaire +1 more source